BridgeBio Pharma, Inc. filed a Form 8-K with the SEC on August 31, 2026, disclosing an agreement with the U.S. government aimed at improving affordability and access to certain of its medicines for Americans.

Key Highlights

  • Agreement announced: BridgeBio entered into an agreement with the U.S. government to improve affordability and access to critical medicines, according to the filing.
  • Orphan drug exclusion: The company disclosed it expects its pricing commitment under the agreement to exclude medicines approved exclusively for orphan indications.
  • Medicaid access expansion: The filing references the company's plans to expand Medicaid access to Attruby through the GENEROUS Model.
  • Pricing mandate expectation: The company stated its expectation that it will not be subject to future pricing mandates under the agreement.
  • Signed by: The filing was signed by Thomas Trimarchi, President and Chief Financial Officer, on August 31, 2026.

BridgeBio Discloses U.S. Government Pricing and Access Agreement Details

On August 31, 2026, BridgeBio Pharma, Inc. (NASDAQ:BBIO) issued a press release, attached as Exhibit 99.1 to the Form 8-K, titled "BridgeBio Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans." The filing was made under Item 8.01 (Other Events) of the Form 8-K and incorporates the press release by reference.

According to the filing, the company expects its pricing commitment for future medicines under the agreement to exclude medicines approved exclusively for orphan indications. The disclosure also references the company's plans to expand Medicaid access to its medicine Attruby through the GENEROUS Model, and the company's expectation that it will not be subject to future pricing mandates as a result of the agreement.

The filing contains forward-looking statements regarding the anticipated implementation, scope, and effects of the agreement. The company noted that "actual results may differ materially from those described in the forward-looking statements," citing risks including the possibility that the agreement may be "implemented, interpreted or applied differently than the Company currently expects," and that federal or state laws or reimbursement frameworks may change in a manner that adversely affects the company. The company also cited risks related to macroeconomic and geopolitical conditions, including hostilities in Ukraine and in Israel and the Middle East, as potential factors affecting outcomes.

What Was Disclosed

BridgeBio Pharma filed an 8-K on August 31, 2026, announcing an agreement with the U.S. government on medicine affordability and access, including a pricing commitment that the company expects will exclude medicines approved solely for orphan indications.